TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06281444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: All patients in both groups will be applied with a home-based exercise program around for 30-minutes per day for four weeks. The exercises that mentioned in the research content are knee range of motion and strengthening exercises for the knee. It will be checked by phone on a weekly basis. Also, each patient in group 1 will receive shockwaves of continuous frequency and intensity (1000 shocks, 2.0 to 3.0 bar,10 Hz and 0.08-0.25mJ/mm2 energy range), while the second group of patients will receive sham-ESWT.~ESWT application will be applied to the medial part of the knee area on the side where the pain is described, or at the patellofemoral and tibiofemoral borders of the affected knee, and will be given in four sessions in total once a week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-ESWT
Description: Sham ESWT application will be set to 1000 pulses, 2-3 bar pressure, 10 Hz frequency and 0 mJ/mm2 energy to be sham.
Study: NCT06000410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Suspension Allograft
Description: This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
Study: NCT06372600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy device
Description: In the shoulder pain points, choose 2 to 3 of them for each treatment, apply the coupling agent, which is convenient for the treatment head to stick to the skin, and complete the longitudinal treatment and horizontal treatment. The setting frequency was 4 \~ 8 Hz, the length of the probe was 15 mm, and the pressure was set at 1.5 mJ/mm2. The frequency of each treatment point reached 2 000 \~ 2 500 times, and the hand-held pressure was set to medium-high level. A total of 6 treatments were completed. For patients with unclear pain points or regional pain, the treatment point should be supraspinatus tendon or infraspinatus tendon, and the treatment should be completed with the most severe pain site.
Study: NCT05411146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-etrumadenant
Description: Administered as specified in the treatment arm.
Study: NCT05700227

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily Adaptive External Beam Radiation Therapy
Description: Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
Study: NCT04759807

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PUR1800 250 ug
Description: The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 250 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PUR1800 500 ug
Description: The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 500 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
Study: NCT06169488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Interbody Fusion
Description: Fusion of one or two lumbar levels with either a transforaminal lumbar interbody fusion (TLIF) or an anterior lumbar interbody fusion (ALIF) procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary rehabilitation
Description: Outpatient multidisciplinary rehabilitation based on the treatment model described by Brox et al and Hellum et al consisting of a cognitive approach and supervised physical and functional training.
Study: NCT06319859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
Study: NCT05229250

Intervention type: OTHER
Intervention: Cycling test
Description: RAMP and MULTI-STAGE test

Intervention type: OTHER
Intervention: Cycling test
Description: RAMP and MULTI-STAGE test

Intervention type: OTHER
Intervention: Occlusion tests
Description: Occlusion test before and after exercise

Intervention type: OTHER
Intervention: Occlusion tests
Description: Occlusion test before and after exercise

Intervention type: DEVICE
Intervention: NIRS during cycling
Description: NIRS devices measuring oxygenation during exercise

Intervention type: DEVICE
Intervention: NIRS during cycling
Description: NIRS devices measuring oxygenation during exercise

Intervention type: DEVICE
Intervention: CPET
Description: Cardiopulmonary exercise testing (heart rate, pulmonary gas exchange) during exercise

Intervention type: DEVICE
Intervention: CPET
Description: Cardiopulmonary exercise testing (heart rate, pulmonary gas exchange) during exercise

Intervention type: DEVICE
Intervention: Echo-Doppler examination
Description: Peak systolic velocity and vascular stiffness measurements in the iliac-aortic tract

Intervention type: DEVICE
Intervention: Echo-Doppler examination
Description: Peak systolic velocity and vascular stiffness measurements in the iliac-aortic tract
Study: NCT06112028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule
Description: On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary therapy
Description: Routine oral aspirin enteric-coated tablets, clopidogrel bisulfate tablets and rosuvastatin calcium tablets (or atorvastatin calcium tablets)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Primary therapy
Description: Routine oral aspirin enteric-coated tablets, clopidogrel bisulfate tablets and rosuvastatin calcium tablets (or atorvastatin calcium tablets)
Study: NCT05102110

Intervention type: DIAGNOSTIC_TEST
Intervention: Oricol Test
Description: Assessment of rectal mucus for material from aero-digestive cancers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oricol Test
Description: Assessment of rectal mucus for material from aero-digestive cancers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oricol Test
Description: Assessment of rectal mucus for material from aero-digestive cancers.
Study: NCT06320314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product (2039125 03)
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
Study: NCT06372600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Autologous Platelet-rich plasma injection was performed under ultrasound guidance

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Autologous Platelet-rich plasma injection was performed under ultrasound guidance
Study: NCT04572165

Intervention type: DRUG
Intervention: Ozempic®
Description: Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.

Intervention type: DRUG
Intervention: Active Comparator
Description: Patients have been treated with commercially available active comparators according to local label and to routine clinical practice at the discretion of the treating physician. Active comparators will include the following antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin. The decision to initiate treatment with commercially available active comparators had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.

Intervention type: DRUG
Intervention: Rybelsus®
Description: Patients have been treated with commercially available Rybelsus® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Rybelsus® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT05497167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Period Kit
Description: This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
Study: NCT06320314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product (2039125 03)
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product (2039125 03)
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
Study: NCT05157009

Intervention type: PROCEDURE
Group type: OTHER
Intervention: implant placement
Description: autogenous bone reconstruction of damaged socket \& simultaneous implant placement

Intervention type: PROCEDURE
Group type: OTHER
Intervention: implant placement
Description: autogenous bone reconstruction of damaged socket \& simultaneous implant placement
Study: NCT04780178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias
Description: A telephone-based acceptance and commitment therapy for caregivers
Study: NCT05741229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized nitroglycerine as adjunctive therapy
Description: Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional therapy for PPHN
Description: patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.
Study: NCT06013098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30%Oxygen
Description: 60%FiO2 in one lung ventilation and 30% FIO2 in both lungs ventilation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 60%Oxygen
Description: 100%FiO2 in one lung ventilation and 60% FIO2 in both lungs ventilation
Study: NCT04793594

Intervention type: OTHER
Intervention: Berg Balance Test
Description: Patients evaluate with Berg Balance Test for balance

Intervention type: OTHER
Intervention: Berg Balance Test
Description: Patients evaluate with Berg Balance Test for balance

Intervention type: OTHER
Intervention: Tinetti Balance And Gait Test
Description: Patients evaluate with Tinetti Balance And Gait Test for balance

Intervention type: OTHER
Intervention: Tinetti Balance And Gait Test
Description: Patients evaluate with Tinetti Balance And Gait Test for balance

Intervention type: OTHER
Intervention: Time Up And Go Test
Description: Patients evaluate with Time Up And Go Test for balance

Intervention type: OTHER
Intervention: Time Up And Go Test
Description: Patients evaluate with Time Up And Go Test for balance
Study: NCT06551662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-coated balloons
Description: Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus drug-coated balloons
Description: Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New generation drug-eluting stent
Description: Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
Study: NCT05272202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Median nerve stimulation
Description: The right-hand median nerve will be stimulated in the same way as for measurement with a conduction velocity or for an evoked potential. Two stimulation electrodes will be placed on the right-hand wrist according to the standards.The stimulation is transcutaneous and painless using the specific Micromed device Sd Ltm Stim Energy (Micromed, Mˆacon, France). The stimulus intensity will range between 3 and 14 mA. The stimulation duration will be 100 ms with a frequency of 0.1 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG measurements
Description: Changes in ERD and ERS patterns during median nerve stimulation according to the various propofol concentrations will be continuously monitored by an EEG amplifier. EEG signals will be acquired using the OpenViBE platform with a Biosemi Active Two 64-channel EEG system, arranged in the Biosemi's ABC system covering the entire scalp at 2048 Hz. Among all recorded sites, some of the electrodes will be localized around the primary motor cortex, the motor cortex, the somatosensory cortex, and the occipital cortex.
Study: NCT04081818

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritious Mushrooms
Description: The Intervention group will consume antioxidant rich and Vitamin D2-enhanced mushrooms as a snack daily for 3 months.
Study: NCT05123118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated intervention of smoking cessation and breastfeeding
Description: The intervention group will receive an integrated intervention of smoking cessation and breastfeeding: education and counseling, monitoring and feedback, and contingent financial incentives.
Study: NCT05628649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Kitchen Collaborative Curriculum
Description: Participants in the intervention arm will first attend 16 weeks of intensive 2-hour classes covering hands-on cooking skills, dietary recommendations (as described within the Harvard Healthy Eating Plate), mindfulness and stress reduction skills, activity and movement techniques, and tools for behavior change. Next, they will attend monthly booster classes for 8 months, with a final assessment for the sustainability of outcomes at 18 months. Sessions will be taught by a combination of a chef educator, dietitian, health coach, or medical doctor.~The study will consist of 2 cohorts of individuals from 4 teaching kitchen program institutions. Each institution will run one-two cycles of the program with each cycle including both a treatment and control group. Each individual cohort will consist of a maximum of 80 individuals; with 40 block-randomized to the intervention and 40 in the control group receiving normal standard of care (followed by their PCP).
Study: NCT05608265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OSNAT 800 IO
Description: Real-time, combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for retinal imaging
Study: NCT05191485

Intervention type: OTHER
Intervention: Qualitative interviews
Description: We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.

Intervention type: OTHER
Intervention: Qualitative interviews
Description: We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.

Intervention type: OTHER
Intervention: Qualitative interviews
Description: We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.

Intervention type: OTHER
Intervention: Qualitative interviews
Description: We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.

Intervention type: OTHER
Intervention: Qualitative interviews
Description: We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.
Study: NCT05123118

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention placebo control
Description: Participants in the control group will receive usual prenatal care from physicians, nurses, or social workers. They will receive best standard care on smoking cessation and breastfeeding, including referral to the New York State Smokers' Quitline and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).
Study: NCT05348382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture
Description: In addition to basis standard pharmacological treatments, intradermal needles will be inserted in each selected acupoint and retained in place for 48 hours. Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster. The operator will tear off the adhesive tape of intradermal needles and stick them on the selected acupoints, and then apply pressure on intradermal needles over the selected acupoints perpendicularly according to the patient's tolerance. In addition, patients will be instructed to press the intradermal needles 4 times per 24 hours throughout the needle retention period, with the aim to increase stimulation for treatment enhancement, each time lasting around 30 seconds.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham intradermal acupuncture
Description: In addition to basis standard pharmacological treatments, sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling. Additionally, participants in the sham intradermal acupuncture group will be treated in another room to avoid direct communications with subjects in the IDA group.
Study: NCT05442164

Intervention type: BEHAVIORAL
Intervention: DANAKIR support network
Description: The DANAKIR intervention will consist of:~* Structured written discharge information~* Invitation to the DANAKIR monthly information meeting DANAKIR meetings The monthly meetings are a core component of the support network. One time each month, a meeting will be held at Herlev Hospital with the participation of an emergency surgeon, an emergency surgery dedicated nurse, a dietician, and a physiotherapist. Each professional (surgeon, nurse, dietician, physiotherapist) will host an informative 15 minute session regarding the postoperative course after major emergency surgery. Following the presentations time for questions in plenum and private with the different experts will be held. Furthermore, there will be an opportunity for networking at the DANAKIR meeting. Each meeting is planned to last 2 hours. At the end of each meeting the patients will be asked to evaluate the meeting and content.
Study: NCT05463185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Stretching exercises along with manual lymphatic drainage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue mobilization
Description: Soft tissue mobilization along with manual lymphatic drainage
Study: NCT05231590

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Description: SARS-CoV-2 recombinant spike protein (12.5 µg) with Advax-SM adjuvant (7.5 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Description: SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Description: SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm